Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the appointment of Michael Binks, M.D., as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience leading global clinical development and translational research across the pharmaceutical and biotechnology sectors.
“Michael is an outstanding addition to Capricor’s leadership team as we advance deramiocel toward potential commercialization for the treatment of Duchenne muscular dystrophy (DMD) and explore future pipeline expansion opportunities,” said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. “With over a decade of leadership in the DMD space, Dr. Binks is uniquely positioned to guide the medical and commercial advancement of our deramiocel program and help shape the next phase of our pipeline. This is a pivotal time to strengthen our medical leadership, and we are excited about the expertise and strategic vision he brings to the organization.”
There, he led global clinical efforts across more than a dozen studies, including several in DMD. His therapeutic expertise spans immunology, neurology, cardiology, nephrology, and hematology. In addition to his pharmaceutical roles, Dr. Binks is the founder of PathfindRx LLC, a translational medicine consultancy, and has held academic and clinical appointments at Addenbrooke’s Hospital in Cambridge and University College London. He earned his medical degree, postgraduate, and specialist training from University College London Medical School.
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream formerly known as CIO News LinkedIn Account | The Mainstream formerly known as CIO News Facebook | The Mainstream formerly known as CIO News Youtube | The Mainstream formerly known as CIO News Twitter |The Mainstream formerly known as CIO News Whatsapp Channel | The Mainstream formerly known as CIO News Instagram
About us:
The Mainstream formerly known as CIO News is a premier platform dedicated to delivering latest news, updates, and insights from the tech industry. With its strong foundation of intellectual property and thought leadership, the platform is well-positioned to stay ahead of the curve and lead conversations about how technology shapes our world. From its early days as CIO News to its rebranding as The Mainstream on November 28, 2024, it has been expanding its global reach, targeting key markets in the Middle East & Africa, ASEAN, the USA, and the UK. The Mainstream is a vision to put technology at the center of every conversation, inspiring professionals and organizations to embrace the future of tech.
